Puma Biotechnology Inc (PBYI)
5.59
-0.01
(-0.18%)
USD |
NASDAQ |
Mar 27, 16:00
5.575
-0.02
(-0.27%)
After-Hours: 20:00
Puma Biotechnology Profit Margin (Quarterly): 17.00% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 17.00% |
September 30, 2023 | 10.33% |
June 30, 2023 | 3.90% |
March 31, 2023 | 2.65% |
December 31, 2022 | -8.54% |
September 30, 2022 | -0.63% |
June 30, 2022 | 15.74% |
March 31, 2022 | -7.44% |
December 31, 2021 | 7.63% |
September 30, 2021 | -96.60% |
June 30, 2021 | -9.56% |
March 31, 2021 | 16.84% |
December 31, 2020 | -28.53% |
Date | Value |
---|---|
September 30, 2020 | -61.99% |
June 30, 2020 | 4.81% |
March 31, 2020 | -33.06% |
December 31, 2019 | -17.80% |
September 30, 2019 | -29.96% |
June 30, 2019 | -69.41% |
March 31, 2019 | -10.18% |
December 31, 2018 | -43.18% |
September 30, 2018 | -22.67% |
June 30, 2018 | -87.33% |
March 31, 2018 | -36.60% |
December 31, 2017 | -296.5% |
September 30, 2017 | -1.27K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-96.60%
Minimum
Sep 2021
17.00%
Maximum
Dec 2023
-14.74%
Average
-7.99%
Median
Profit Margin (Quarterly) Benchmarks
ADMA Biologics Inc | -23.88% |
Regeneron Pharmaceuticals Inc | 33.77% |
CytomX Therapeutics Inc | 3.15% |
Entrada Therapeutics Inc | -22.81% |
Sarepta Therapeutics Inc | 11.51% |
Profit Margin (Quarterly) Related Metrics
Return on Equity | 63.49% |
Return on Assets | 10.25% |
Return on Invested Capital | 16.24% |
Gross Profit Margin (Quarterly) | 66.30% |
Operating Margin (Quarterly) | 20.50% |
Return on Net Operating Assets | 17.72% |